冲刺连续30天净流入，中药ETF(159647)盘中净申购200万份

Group 1 - The core viewpoint of the articles highlights the performance of the Chinese medicine sector, particularly the 中证中药指数 (CSI Traditional Chinese Medicine Index), which shows mixed results among its constituent stocks, with 千金药业 (Qianjin Pharmaceutical) leading the gains at 1.92% [1] - 中药ETF (Traditional Chinese Medicine ETF) has seen a recent price of 0.99 yuan, with a net subscription of 2 million units during the trading session, indicating a continuous inflow for 30 days [1] - A significant study published in the journal "Phytomedicine" by a team from the China Academy of Chinese Medical Sciences demonstrates the clinical benefits of 中药复方新加达原散 (Xinjia Dayuan Powder) in improving microbial clearance rates, suggesting its potential as an auxiliary treatment option [1] Group 2 - 万联证券 (Wanlian Securities) recommends focusing on innovative drugs and devices, particularly in major fields such as oncology, autoimmune diseases, and metabolic disorders, as well as new technology platforms like ADCs and gene therapies [2] - The report emphasizes the importance of 中医药 (Traditional Chinese Medicine), particularly companies with strong brand moats and modernization capabilities, in light of supportive policies [2] - As of September 30, 2025, the top ten weighted stocks in the 中证中药指数 account for 55.08% of the index, with notable companies including 云南白药 (Yunnan Baiyao) and 片仔癀 (Pianzaihuang) [2]